Key result
VTE linked to ~4-fold higher risk of bleeding in advanced lung cancer.
Why the study?
Hemorrhagic events occur during advanced lung cancer treatment, but few studies have evaluated their risk factors, particularly given that cancer-related thromboembolism requires anticoagulant monitoring.
Does concurrent venous thromboembolism increase the risk of hemorrhagic events in patients with advanced lung cancer?
Observational (n=1,008)
Yes
Does concurrent venous thromboembolism increase the risk of hemorrhagic events in patients with advanced lung cancer?
In Japanese patients with advanced lung cancer, concurrent venous thromboembolism substantially increases the risk of subsequent bleeding events, underscoring the need for careful risk-benefit evaluation of anticoagulation.
Answers are grounded in this paper and cite their sources.
VTE was associated with higher bleeding risk in advanced lung cancer; leaves open whether anticoagulation thresholds warrant adjustment pending prospective trials.
Despite the occurrence of various hemorrhagic events during advanced lung cancer treatment, few researchers have reported on their risk factors. Moreover, the development of cancer-related thromboembolism indicates anticoagulant use. However, adverse events such as bleeding should be monitored. In this study, we aimed to identify factors that influence the onset of hemorrhagic events in patients with lung cancer. The Rising-VTE/NEJ037 study was a multicenter, prospective, observational study. A total of 1008 patients with lung cancer who were unsuitable for radical resection or radiation were enrolled and followed up for 2 years. Multivariate analysis using a Cox proportional hazard model was performed to compare the outcomes of the time to the onset of hemorrhagic events for 2 years after registration. Hemorrhagic events occurred in 115 patients (11.4%), with 35 (30.4%) experiencing major bleeding. Significant risk factors included venous thromboembolism (VTE) (hazard ratio [HR]: 4.003, p < 0.001) and an Eastern Cooperative Oncology Group Performance Status score of 1 (HR: 2.476, p < 0.001). Factors that significantly reduced hemorrhagic event risk were female sex (HR: 0.454, p = 0.002) and M1a status (HR: 0.542, p = 0.038). VTE is a risk factor for hemorrhagic events in patients with advanced lung cancer, and risks associated with anticoagulant therapy should be considered.
No takes yet. Share an insight, caveat, or question.
Kawakado et al. (2024) conducted an observational in Advanced lung cancer (n=1,008). Venous thromboembolism (VTE) vs. No venous thromboembolism was evaluated on Time to the onset of hemorrhagic events (HR 4.003, p=<0.001). Venous thromboembolism increased the risk of hemorrhagic events in patients with advanced lung cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: